Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Urinary Bladder Neoplasms: HELP
Alexandra Drakaki
Based on 8 articles published since 2008
||||
Expertise Level
The expertise of Alexandra Drakaki ranks in the Graphical view (beta)
Uncounted papers?
Work Locations
Details
Most likely:    UCLA   Contact    
2018
  • Department of Urology. · Institute of Urologic Oncology. · Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. · Pubmed 29416316
  • Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address: · Pubmed 29199023
  • Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · , 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. · Pubmed 29752514
  • Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Pubmed 29299664
2017
  • Yale University School of Medicine, New Haven, CT, USA. Electronic address: · Erasmus MC Cancer Institute, Rotterdam, Netherlands. · British Columbia Cancer Agency, Vancouver, BC, Canada. · David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. · San Camillo and Forlanini Hospitals, Rome, Italy. · University of Tsukuba, Tsukuba, Ibaraki, Japan. · Hospital Universitario 12 de Octubre (CiberOnc), Madrid, Spain. · Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK. · Centre Léon Bérard, Lyon, France. · National and Kapodistrian University of Athens, Athens, Greece. · University of Washington, Seattle, WA, USA. · Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · National Cancer Centre Hospital East, Chiba, Japan. · PA Herzen Moscow Oncological Research Institute, Moscow, Russia. · Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. · National Institute of Oncology, Budapest, Hungary. · Taichung Veterans General Hospital, Taichung, Taiwan. · Akdeniz University School of Medicine, Antalya, Turkey. · Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan. · University Hospital, Tübingen, Germany. · Florida Cancer Specialists, Port Charlotte, FL, USA. · Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea. · Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. · RBHI Ivanovo Regional Oncology Dispensary, Ivanovo, Russia. · Centre Oscar Lambret, Lille, France. · Rambam Health Care Campus, Haifa, Israel. · University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy. · Tatarstan Regional Cancer Centre, Kazan, Russia. · Institut Català d'Oncologia L'Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain. · Hospital del Mar, Barcelona, Spain. · Trakya University, Edirne, Turkey. · Inonu University, Malatya, Turkey. · Eli Lilly and Company, Indianapolis, IN, USA. · Barts Cancer Institute, Queen Mary University of London, London, UK. · Pubmed 28916371
  • Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. · Accelerated Medical Diagnostics Incorporated, Berkeley, California. · Lawrence Livermore National Laboratory, Livermore, California. · The Jackson Laboratory, Sacramento, California. · Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, California. · Division of Hematology and Oncology, UCLA Medical Center, Los Angeles, California. · Department of Urology, UCLA Medical Center, Los Angeles, California. · Department of Urology, University of California Davis, Sacramento, California. · Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. · VA Northern California Health Care System, Mather, California. · Pubmed 27903751
2016
  • Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France · Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ · Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT · Saeed Rafii, Sarah Cannon Research Institute, London, UK · Zev A. Wainberg and Alexandra Drakaki, University of California, Los Angeles · and Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA · Jason Luke and Peter H. O'Donnell, University of Chicago Comprehensive Cancer Center, Chicago, IL · Tyler J. Curiel, The University of Texas Health Science Center, San Antonio, TX · Gerardo Colon-Otero and Winston Tan, Mayo Clinic, Jacksonville, FL · Rachel E. Sanborn, Providence Cancer Center, Portland, OR · John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD · and Neil H. Segal, Memorial Sloan Kettering Cancer Center, New York, NY. · Pubmed 27269937
Probable:    Harvard University   Contact    
2013
  • Beth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA. · Pubmed 23519772
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of all articles written by Alexandra Drakaki in 2008-2019 about Urinary Bladder Neoplasms:

  • Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. 2018
  • The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. 2018
  • Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. 2018
  • Trends in urinary diversion after radical cystectomy for urothelial carcinoma. 2018
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. 2017
  • Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. 2017
  • Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. 2016
  • Novel immunotherapies in GU malignancies. 2013
Show List of Full Article Records
Google Searches

Learn more about Alexandra Drakaki using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
UCLA
Harvard University
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
UCLA
2018
  • Department of Urology. · Institute of Urologic Oncology. · Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. · Pubmed 29416316
  • Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. · Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address: · Pubmed 29199023
  • Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · , 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Division of Urology, Department of Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA. · Pubmed 29752514
  • Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, USA. · Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA. · Institute of Urologic Oncology, University of California, Los Angeles, USA. · Pubmed 29299664
2017
  • Yale University School of Medicine, New Haven, CT, USA. Electronic address: · Erasmus MC Cancer Institute, Rotterdam, Netherlands. · British Columbia Cancer Agency, Vancouver, BC, Canada. · David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. · San Camillo and Forlanini Hospitals, Rome, Italy. · University of Tsukuba, Tsukuba, Ibaraki, Japan. · Hospital Universitario 12 de Octubre (CiberOnc), Madrid, Spain. · Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK. · Centre Léon Bérard, Lyon, France. · National and Kapodistrian University of Athens, Athens, Greece. · University of Washington, Seattle, WA, USA. · Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. · National Cancer Centre Hospital East, Chiba, Japan. · PA Herzen Moscow Oncological Research Institute, Moscow, Russia. · Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. · National Institute of Oncology, Budapest, Hungary. · Taichung Veterans General Hospital, Taichung, Taiwan. · Akdeniz University School of Medicine, Antalya, Turkey. · Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, Tainan, Taiwan. · University Hospital, Tübingen, Germany. · Florida Cancer Specialists, Port Charlotte, FL, USA. · Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea. · Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy. · RBHI Ivanovo Regional Oncology Dispensary, Ivanovo, Russia. · Centre Oscar Lambret, Lille, France. · Rambam Health Care Campus, Haifa, Israel. · University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy. · Tatarstan Regional Cancer Centre, Kazan, Russia. · Institut Català d'Oncologia L'Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain. · Hospital del Mar, Barcelona, Spain. · Trakya University, Edirne, Turkey. · Inonu University, Malatya, Turkey. · Eli Lilly and Company, Indianapolis, IN, USA. · Barts Cancer Institute, Queen Mary University of London, London, UK. · Pubmed 28916371
  • Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. · Accelerated Medical Diagnostics Incorporated, Berkeley, California. · Lawrence Livermore National Laboratory, Livermore, California. · The Jackson Laboratory, Sacramento, California. · Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, California. · Division of Hematology and Oncology, UCLA Medical Center, Los Angeles, California. · Department of Urology, UCLA Medical Center, Los Angeles, California. · Department of Urology, University of California Davis, Sacramento, California. · Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California. · VA Northern California Health Care System, Mather, California. · Pubmed 27903751
2016
  • Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France · Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ · Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT · Saeed Rafii, Sarah Cannon Research Institute, London, UK · Zev A. Wainberg and Alexandra Drakaki, University of California, Los Angeles · and Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA · Jason Luke and Peter H. O'Donnell, University of Chicago Comprehensive Cancer Center, Chicago, IL · Tyler J. Curiel, The University of Texas Health Science Center, San Antonio, TX · Gerardo Colon-Otero and Winston Tan, Mayo Clinic, Jacksonville, FL · Rachel E. Sanborn, Providence Cancer Center, Portland, OR · John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD · and Neil H. Segal, Memorial Sloan Kettering Cancer Center, New York, NY. · Pubmed 27269937
Unspecified
2018
  • Department of Urology. · Institute of Urologic Oncology. · Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. · Pubmed 29416316
Harvard University
2013
  • Beth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA. · Pubmed 23519772
Yearly article counts 042100100000
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.